Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Cholangitis Post Kasai in Biliary Atresia)

Not yet recruiting

• Conditions: Biliary Atresia, Kasai Portoenterostomy Status; Cholangitis

• Registration Number: NCT07129655
• Lead Sponsor: University Hospital, Geneva

Brief Summary

Biliary atresia is a rare liver disease affecting newborns. In those babies bile ducts are blocked, and bile cannot flow from the liver to the intestines. Biliary atresia patients require a special surgery called "Kasai operation" to restore the bile flow. A common and serious problem after surgery is an infection of the bile ducts, called cholangitis, which can damage the liver and lead an earlier need for liver transplantation.

In 2022, a group of international experts led by the Swiss Pediatric Liver Center from the HUG created new guidelines to help identify and treat cholangitis more consistently.

This study will test how well these new definitions work in real life of hospitals. Over one year, physicians will collect data on children in whom they suspect cholangitis in the first year after their Kasai. The goal is to see whether these new definitions are applicable in the clinical setting.

The study will involve around 40 patients and will use secure methods to store data. The findings will help improve how cholangitis is diagnosed and treated, making care more effective and consistent for children with biliary atresia.

Detailed Description

This prospective, observational study will be conducted across hospitals managing pediatric biliary atresia patients. Data on suspected cholangitis cases in the first year post Kasai hepatoportoenterostomy will be collected by mini-teams of three healthcare providers over twelve months. Data will be anonymized, and the study will adhere to international ethical standards.

Inclusion Criteria:

* Patients with biliary atresia suspected of cholangitis within one year post Kasai hepatoportoenterostomy.

* Data from specialties including pediatric surgery, pediatric hepatology, and pediatric emergency care.

Exclusion Criteria:

• Recurrent cholangitis or cholangitis after one-year post Kasai hepatoportoenterostomy.

Definitions: Cholangitis will be defined by clinical confirmation, improvement with antimicrobial therapy, and lab value changes.

Primary Aim: To assess the application of consensus definitions for suspected and confirmed cholangitis.

Secondary Aim: To evaluate the proposed duration of treatment for cholangitis and compare it to clinical practice.

Data Collection: Data will be stored using the secure REDCap platform, managed by the University of Geneva. Local investigators are responsible for ethical approvals.

Expected Results: This study will assess the practicality of applying expert panel definitions for cholangitis after Kasai hepatoportoenterostomy and gather feedback from clinicians. A sample size of 40 patients is targeted, with 20 in each group (suspected and confirmed). Findings will help refine diagnostic criteria.

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-08-11
• Study First Submitted QC: 2025-08-11
• Last Update Submitted: 2025-08-11
• Study First Posted: 2025-08-19
• Last Update Posted: 2025-08-19
• Study Start: 2025-10-01
• Primary Completion: 2026-09-30
• Study Completion: 2026-09-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• patients with a suspected diagnosis cholangitis within 1 year after Kasai hepatoportoenterostomy

Exclusion Criteria

• recurrent cholangitis, cholangitis >1 year after Kasai

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess the applicability of the definitions for suspected and confirmed cholangitis.	12 months

Secondary Outcome Measures

Name	Time	Method
Duration of treatment for suspected and confirmed cholangitis	1 year

Trial Locations

Locations (1)

Hôpitaux Universitaires de Genève; 🇨🇭 Geneva, Switzerland